Skip to Content
MilliporeSigma

H1120000

Hydralazine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1-Hydrazinophthalazine hydrochloride

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

20 MG

$175.00

$175.00

Check Cart for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C8H8N4 · HCl
CAS Number:
304-20-1
Molecular Weight:
196.64
NACRES:
NA.24
PubChem Substance ID:
329815153
UNSPSC Code:
41116107
MDL number:
MFCD00135998

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5,7H,9H2;1H/b11-8-;

SMILES string

Cl[H].N\N=C1/N=NC=C2C=CC=CC12

InChI key

SECXUXOCDLQOBI-MKFZHGHUSA-N

grade

pharmaceutical primary standard

API family

hydralazine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
1313006H1753PHR3184
Hydralazine hydrochloride European Pharmacopoeia (EP) Reference Standard

H1120000

Hydralazine hydrochloride

Hydralazine hydrochloride United States Pharmacopeia (USP) Reference Standard

USP

1313006

Hydralazine hydrochloride

Hydralazine hydrochloride

Sigma-Aldrich

H1753

Hydralazine hydrochloride

Hydralazine Hydrochloride pharmaceutical secondary standard, certified reference material

Supelco

PHR3184

Hydralazine Hydrochloride

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

-

grade

certified reference material, pharmaceutical secondary standard

manufacturer/tradename

EDQM

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

-

format

neat

format

neat

format

-

format

-

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical

API family

hydralazine

API family

hydralazine

API family

-

API family

hydralazine

storage temp.

2-8°C

storage temp.

-

storage temp.

-

storage temp.

2-30°C

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Hydralazine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Inhibits DNA methyltransferase and modulates epigenetic regulation of gene expression. Non-selective MAO-A/B inhibitor; antihypertensive; semicarbazide-sensitive amine oxidase inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones
GHS06

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sofie Gevaert et al.
Acta cardiologica, 69(2), 193-196 (2014-05-03)
Heart failure is an established predictor of primary cardiac events during pregnancy. Adequate heart failure treatment in pregnant women is hampered by important foetotoxicity of several conventional drugs. Hydralazine with or without long-acting nitrates has been proposed as an alternative
Hydralazine and hydralazine hydrochloride.
IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, 24, 85-100 (1980-01-01)
Genetic mechanisms possibly leading to racially different responses to nitrate therapy.
Gustavo H Oliveira-Paula
The American journal of cardiology, 114(7), 1126-1126 (2014-09-13)
Keith C Ferdinand
Expert review of cardiovascular therapy, 3(6), 993-1001 (2005-11-19)
In the USA alone, there are over 5,000,000 people diagnosed with heart failure. A disproportionate number of African-Americans are affected by this disease, with increased morbidity and mortality, yet they are tremendously under-represented in clinical trials. Several drugs have been
Keith Copelin Ferdinand et al.
The American journal of cardiology, 114(1), 151-159 (2014-05-23)
The 2013 American College of Cardiology Foundation/American Heart Association guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce mortality and morbidity for African-Americans with symptomatic heart failure (HF) and reduced ejection fraction, currently receiving optimal medical therapy (class I
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service